Where Will Iovance Biotherapeutics Stock Be in 5 Years? [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deeply unprofitable, only recently obtaining approval from regulators for one of its treatments. Below, I'll look at what the business may look like five years from now, whether it could be profitable, and if it's worth investing in the stock today. Could more approvals be coming? Iovance investors got great news in February when the Food and Drug Administration approved Amtagvi (lifileucel), the company's cell therapy for unresectable or metastatic melanoma. It's an important milestone for the business to have an approved treatment in its portfolio, and there could be more to come for Iovance. The company has many ongoing trials involving lifileucel and another drug, LN-145, for other types of cancers; these include cervical, head and neck, and non-small cell lung cancer. Iovance has more than a dozen trials underway, and while many of them are
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi [Seeking Alpha]Seeking Alpha
- Why Iovance Stock Is Down 18% Today [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 5/9/24 - Beat
IOVA
Sec Filings
- 5/10/24 - Form S-8
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- IOVA's page on the SEC website